Asthma inflammatory phenotypes on four continents: most asthma cases are non-eosinophilic - Pembrey, Lucy; Brooks, Collin; Mpairwe, Harriet; Figueiredo, Camila A; Oviedo, Aida Y.; Chico, Martha; Ali, Hajar; Nambuya, Irene; Tumwesige, Pius; Robertson, Steven; Ring, Susan; Barreto, Mauricio L.; et al. (medRxiv, 2020)
We have assessed asthma inflammatory phenotypes in five centres in Brazil, Ecuador, Uganda, New Zealand and the United Kingdom. We recruited 998 asthmatics and 356 non-asthmatics: 204/40 in Brazil, 176/67 in Ecuador, 235/132 in New Zealand, 207/50 in Uganda, and 176/67 in the United Kingdom. All centres studied children and adolescents (age-range 8-20 years), with the exception of the UK centre, which involved 26-27 year olds. Sputum induction testing was conducted, with 87% providing a sputum sample, ranging from 74% (Brazil) to 93% (United Kingdom); of these, 71% were countable. The proportion of asthmatics classified as eosinophilic or mixed granulocytic asthma (i.e. eosinophilic asthma (EA)) was 39% (95% confidence interval 35%-43%) overall: 35% in Brazil, 32% in Ecuador, 50% in New Zealand, 33% in Uganda, and 33% in the United Kingdom. The non-eosinophilic asthmatics (NEA) had similar severity/control to the eosinophilic asthmatics (EA). Of the 61% (95%CI 57%-65%) of cases with NEA, 50% showed no signs of inflammation (paucigranulocytic), with 11% having neutrophilic inflammation. This is the first time that sputum induction has been used in a standardised manner to compare asthma inflammatory phenotypes in high income countries (HICs) and low-and-middle-income countries (LMICs). It confirms that most cases are non-eosinophilic. This has potentially major implications for asthma prevention and management in both of these contexts, and supports the urgent need to recognise that asthma is a heterogeneous condition, and to develop new prevention strategies and new therapies which target NEA.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe World ASthma Phenotypes (WASP) collaboration is based on the AsthmaPhenotypes study which is funded by the European Research Council under the European Union Seventh Framework Programme (FP7/2007-2013) / ERC grant agreement no 668954. ALSPAC: We are extremely grateful to all the families who took part in this study, the midwives for their help in recruiting them, and the whole ALSPAC team, which includes interviewers, computer and laboratory technicians, clerical workers, research scientists, volunteers, managers, receptionists and nurses. The UK Medical Research Council and Wellcome (Grant ref: 102215/2/13/2) and the University of Bristol provide core support for ALSPAC. Alison Elliott and Philip Cooper were funded by Wellcome Trust grant numbers 095778 and 088862, respectively. Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:London School of Hygiene and Tropical Medicine Research Ethics CommitteeAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData is currently not available. We will consider requests for data sharing after the main findings have been published.